BRAF V600E Mutation in Ganglioglioma: Impact on Epileptogenicity and Implications for Surgical Strategy
European Journal of Neurology · 2025
DOI: 10.1111/ene.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Matthias Tomschik und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Ganglioglioma, Proto-Oncogene Proteins B-raf, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical University of Vienna Comprehensive Center for Pediatrics Starter Grant.
Abstract (Originalsprache)
Objective
Gangliogliomas are commonly found pathologies in patients undergoing epilepsy surgery. While resections can be curative, seizure relapses occur. Expression of CD34 and the BRAF V600E mutation are the most common molecular biomarkers found in gangliogliomas, but their influence on seizure outcomes is unclear. We therefore reviewed our experience over two decades to better describe prognostic factors.
Methods
We performed a retrospective chart review of all patients operated on for ganglioglioma at our institution since the year 2000. We included patients with preoperative epilepsy and a minimum follow‐up of 1 year. Available tumor specimens were immunohistochemically stained for CD34 and BRAF V600E.
Results
We included 62 patients with epilepsy operated for ganglioglioma. Lesionectomies were performed in 32 (51.6%), extended resections in 21 (33.9%), and partial resections in 9 cases (14.5%). Residual tumor mass on postoperative MRI was diagnosed in 21 patients (33.9%). CD34 reactivity was found in 57 patients (91.9%) and the BRAF V600E mutation was detected in 30 patients (48.4%). Patients with a BRAF V600E mutation were younger at the time of epilepsy onset (9.1 years vs. 15.2 years) and surgery (14.5 years vs. 23.7 years). Residual tumor was the largest risk factor for seizure relapses (hazard ratio 8.45) and the BRAF V600E mutation also increased this risk (hazard ratio 3.94).
Conclusions
BRAF V600E status in patients with ganglioglioma‐associated epilepsy is a potential biomarker to stratify the risk for seizure relapse after surgery. BRAF V600E‐positive patients might benefit from a more aggressive surgical strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.
- Department of Pediatrics and Adolescent Medicine, Full Member of ERN EpiCARE, Medical University of Vienna, Vienna, Austria.
- Department of Neuroradiology, Medical University of Vienna, Vienna, Austria.
- Department of Neurology, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Matthias Tomschik
Förderung
- Medical University of Vienna Comprehensive Center for Pediatrics Starter Grant
Zitieren
APA
Tomschik, M., Horner, E., Lang, A., Mayer, F., Czech, T., Kasprian, G., Pataraia, E., Azizi, A. A., Feucht, M., Rössler, K., Haberler, C., & Dorfer, C. (2025). BRAF V600E Mutation in Ganglioglioma: Impact on Epileptogenicity and Implications for Surgical Strategy. European Journal of Neurology. https://doi.org/10.1111/ene.70136
Vancouver
Tomschik M, Horner E, Lang A, Mayer F, Czech T, Kasprian G, et al. BRAF V600E Mutation in Ganglioglioma: Impact on Epileptogenicity and Implications for Surgical Strategy. European Journal of Neurology. 2025. doi:10.1111/ene.70136
BibTeX
@article{Tomschik2025,
author = {Tomschik, Matthias and Horner, Eva and Lang, Alexandra and Mayer, Florian and Czech, Thomas and Kasprian, Gregor and Pataraia, Ekaterina and Azizi, Amedeo A and Feucht, Martha and Rössler, Karl and Haberler, Christine and Dorfer, Christian},
title = {BRAF V600E Mutation in Ganglioglioma: Impact on Epileptogenicity and Implications for Surgical Strategy},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70136}
}
EUVIMED